GLP1R and diabetes mellitus: The incretin-based therapies, which include DPP-IV inhibitors [120] and GLP-1 receptor (GLP-1R) agonists [121], are a new class of antidiabetic medications, which aim to ameliorate the “incretin defect” present in people with diabetes [122].